Skip to main content
Log in

SR140333, a Substance P Receptor Antagonist, Influences Morphological and Motor Changes in Rat Experimental Colitis

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

The etiology of inflammation, edema, and smoothmuscle contraction characteristic of inflammatory boweldisease is not clearly understood. There is evidencethat several neuropeptides, including substance P (SP), may play a role. In this study weevaluated the ability of a SP-antagonist (SR140333) tomodify the course of experimental colitis induced in therat by trinitrobenzene sulfonic acid (TNB). Colitis was induced in 24 rats using TNB applied byintrarectal enema. Twelve TNB-treated rats receivedSR140333, 0.1 mg/kg intraperitoneally, 30 min before theadministration of TNB and every 48 hr until death. Twelve rats receiving only intrarectal 0.9%saline served as controls. Rats of each group werekilled after 14 days. At day 14, the control groupshowed no signs of inflammation whereas the TNB-treated rats without SR140333 treatment exhibited awell-established colitis. The TNB-treated group had ahigher level of inflammation, as seen histologically andby the significantly greater weight of colon strips, compared to the controls (0.30 ± 0.09 gvs 0.13 ± 0.03 g, P < 0.001) and to theSR140333-treated rats (0.30 ± 0.09 g vs 0.14± 0.05 g, P < 0.001). In addition, smoothmuscle contractility was significantly reduced in the inflamedcolons of TNB-treated rats when compared with thecontrols (carbachol: 42.7 ± 20.3 vs 254.2± 69.78 mg/mm2± 10.02 vs 89.45± 23.17 mg/mm2 11.4 ± 2.2 vs 98.32 ± 33.57mg/mm21). However, SR140333-treated ratsshowed a recovery from inflammation and motoralterations caused by TNB (carbachol: 150.9 ±46.1 mg/mm21; SP: 32.5 ± 9.4 mg/mm25; KCl:125.7 ± 36.1 mg/mm21). In conclusion,treatment with SP antagonist SR140333 reduces theseverity of colitis and has beneficial effects on theconcomitant alterations of contractility. Thus, theblockade of substance P may represent a possibility inthe treatment of intestinal inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Chaudary NA, Travelor SC: Human colonic motility: a comparative study of normal subjects, patients with ulcerative colitis and patients with irritable bowel syndrome. I. Resting patterns of motility. Gastroente rology 40:1–17, 1961

    Google Scholar 

  2. Grossi L, McHugh K, Collins SM: On the specificity of altered muscle function in experimental colitis in rats. Gastroenterology 104:1049–1056, 1993

    Google Scholar 

  3. Vermillion D, Collins SM: Increased responsiveness of jejunal longitudinal muscle in Trichinella-infected rats. Am J Physiol 254:G124–G129, 1988

    Google Scholar 

  4. Weihe E, Kre kel J: The neuroimmune connection in human tonsils. Brain Behav Immun 5:41–54, 1991

    Google Scholar 

  5. Hagermark O, Hokfelt T, Pernow B: Flare and itch induced by substance P in human skin. J Invest Dermatol 71:233–235, 1978

    Google Scholar 

  6. Lembeck F, Holzer P: Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn-Schmie deberg's Arch Pharmacol 310:175–183, 1979

    Google Scholar 

  7. Lembeck F: Substance P and sensory neurons. In Substance P. Metabolism and Biological Actions. CC Jordan, P Oehme (eds). London, Taylor and Francis, 1985, pp 137–151

    Google Scholar 

  8. Levine JD, Moskowitz MA, Basbaum AI: The contribution of neurogenic inflammation in experimental arthritis. J Immunol 135:843s-846s, 1985

    Google Scholar 

  9. Mandahl A, Bill A: Ocular response s to antidromic trigeminal stimulation, intracameral prostaglandin E1 and E2, capsaicin and substance P. Acta Physiol Scand 112:331–338, 1981

    Google Scholar 

  10. Büchler M, Weihe E, Friess H, Malfertheiner P, Bockman DE, Müller S, Nohr D, Beger HG: Changes in peptidergic innervation in chronic pancreatitis. Pancreas 7:183–192, 1992

    Google Scholar 

  11. Fink T, Di Sebastiano P, Büchler MW, Beger HG, Weihe E: Growth-associated protein-43 and protein gene-product 9.5 innervation in human pancreas: Changes in chronic pancreatitis. Neuroscience 63(1):249–266, 1994

    Google Scholar 

  12. Di Sebastiano P, Fink T, Weihe E, Frie ss H, Beger HG, Büchler M: Changes of protein gene product 9.5 in the inflamed appendix. Dig Dis Sci 40(2):366–372, 1995

    Google Scholar 

  13. Di Sebastiano P, Fink T, Weihe E, Frie ss H, Innocenti P, Beger HG, Büchler MW: Immune cells infiltration and growth associated protein-43 correlate with pain in chronic pancreatitis. Gastroenterology 112:1648–1655, 1997

    Google Scholar 

  14. Bjorck S, Dahlstrom A, Johansson L, Ahlman H: Treatment of the mucosa with local anesthetics in ulcerative colitis. Agents Actions 35(suppl):C60–C72, 1992

    Google Scholar 

  15. Pernov B: Substance P: Present status and future prospects. In Substance P. Metabolism and Biological Actions. CC Jordan, P Oehme (eds). London, Taylor and Francis, 1985, pp 187–196

    Google Scholar 

  16. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795–803, 1989

    Google Scholar 

  17. Emonds-Alt X, Doutremepuich JD, Heaulme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux JP, Proietto V, Van Broek D, Soubrié P, Le Fur G, Brelière JC: In vitro and in vivo biological activities of SR 140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. Eur J Pharmacol 250:403–413, 1993

    Google Scholar 

  18. Barrett KE: Neurogenic inflammation in the intestine. Gastroenterology 108:295–296, 1995

    Google Scholar 

  19. McCafferty DM, Sharkey KA, Wallace JL: Beneficial effects of local or systemic lidocaine in experimental colitis. Am J Physiol 266:G560–G567, 1994

    Google Scholar 

  20. Pothoulakis C, Castagliuolo I, LaMont TJ, Jaffer A, O'Keane JC, Snider RM, Leeman SE: CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin but not cholera toxin. Proc Natl Acad Sci USA 91:947–951, 1994

    Google Scholar 

  21. Wallace JL, MacNaughton WK, Morris GP, Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96:29–36, 1989

    Google Scholar 

  22. Higa A, McKnight GW, Wallace JL: Attenuation of epithelial injury in acute experimental colitis by immunomodulators. Eur J Pharmacol 239:171–176, 1993

    Google Scholar 

  23. Elson CO, Balfour Sartor R, Tennyson GS, Riddel RH: Experimental models of inflammatory bowel disease. Gastroenterology 109:1344–1367, 1995

    Google Scholar 

  24. Fax-Robichaud AE, Collins SM: Altered calcium-handling properties of jejunal smooth muscle from nematode-infected rats. Gastroenterology 91:1462–1469, 1986

    Google Scholar 

  25. Cohen JD, Kao HW, Tau ST, Lechago J, Snape WS: Effects of acute experimental colitis on rabbit colonic smooth muscle. Am J Physiol 251:G538–G545, 1986

    Google Scholar 

  26. Renzi D, Calabro A, Panerai C, Tramontana M, Evangelista S, Milani S, Surrenti C: De creased substance P and neurokinin A tissue levels are associated with enhanced beta-preprotachikinin gene expression in experimental TNB-colitis. Gastroenterology 108:A902, 1995

    Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Di Sebastiano, P., Grossi, L., Di Mola, F.F. et al. SR140333, a Substance P Receptor Antagonist, Influences Morphological and Motor Changes in Rat Experimental Colitis. Dig Dis Sci 44, 439–444 (1999). https://doi.org/10.1023/A:1026639509036

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026639509036

Navigation